The partnership between Xceleron and JCL Bioassay isexpected to provide access to clinical design expertise and the mostappropriate analytical platform for the purpose of early clinicalinvestigation. Adding to the value ofthe partnership, Xceleron and JCL Bioassay have, between them, developed morethan 100 analytical methods for Phase 0 and enriched Phase 1 investigations,and both companies have recently built, equipped and staffed laboratoriesspecifically for the purpose of ultra-low level analyses under GLP and GCPconditions.
"This partnership emphasizes the critical role ofcontemporary analytical platforms in driving down the cost of drug development,"said Dr. Michael Butler, CEO of Xceleron. "Whether in Phase 0 or enriched PhaseI, we can confidently provide critical PK and PD information before Phase II."
"With 27 years' experience in providing servicesfor bioassay work coupled with-state-of-the-art analytical instruments, ourresearchers are well-positioned to conduct ultrasensitive bioanalyses. This has led to the continuous growth of ourcompany as a leader in the bioanalytical field and enables our customers tomakerapid and precise decisions on their drug development programs," said JennyLin, vice president of operations and chief scientific officer of JCL BioassayUSA, Inc. "The partnership with Xceleron further expands the geographic andtechnological scope of the services we can provide to our customers andpromotes the use of these cutting-edge analytical platforms to detect low-levelanalytes in early drug development."
